Johnson & Johnson Performance dei guadagni passati

Il passato criteri di controllo 3/6

Gli utili di Johnson & Johnson sono diminuiti a un tasso medio annuo di -1.9%, mentre il settore Pharmaceuticals ha visto gli utili crescere a un tasso medio annuo di 1.2%. I ricavi sono cresciuti crescere a un tasso medio annuo di 0.7%. Il ritorno sul capitale proprio di Johnson & Johnson è 21% e ha margini netti di 16.8%.

Informazioni chiave

-1.9%

Tasso di crescita degli utili

-0.5%

Tasso di crescita dell'EPS

Pharmaceuticals Crescita del settore	6.0%
Tasso di crescita dei ricavi	0.7%
Rendimento del capitale proprio	21.0%
Margine netto	16.8%
Prossimo aggiornamento sui guadagni	22 Jan 2025

Aggiornamenti sulle prestazioni recenti

Recent updates

How To Build A $25,000 Dividend Portfolio, Johnson & Johnson As Your Core Holding

Nov 28

Ripartizione dei ricavi e delle spese

Come Johnson & Johnson guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

NYSE:JNJ Ricavi, spese e utili (USD Millions )
Data	Ricavi	Guadagni	Spese G+A	Spese di R&S
29 Sep 24	87,696	14,767	21,290	16,414
30 Jun 24	86,576	16,382	21,050	14,909
31 Mar 24	85,648	17,072	20,640	15,172
31 Dec 23	85,159	13,326	20,166	15,085
01 Oct 23	83,703	12,421	19,648	14,315
02 Jul 23	82,348	12,422	19,323	14,353
02 Apr 23	77,458	10,730	17,993	14,128
01 Jan 23	79,990	16,370	19,078	14,135
02 Oct 22	84,855	17,879	21,037	15,145
03 Jul 22	88,197	17,236	22,197	15,082
03 Apr 22	94,880	19,830	24,430	14,998
02 Jan 22	78,740	17,801	19,506	14,277
03 Oct 21	91,446	17,880	23,364	14,026
04 Jul 21	89,190	17,767	22,852	13,444
04 Apr 21	84,214	15,115	21,817	12,757
03 Jan 21	82,584	14,714	21,731	12,159
27 Sep 20	80,856	16,986	21,681	11,359
28 Jun 20	80,503	15,185	21,625	11,118
29 Mar 20	82,729	17,166	22,185	11,077
29 Dec 19	82,059	15,119	21,885	11,355
29 Sep 19	81,706	14,151	21,957	11,347
30 Jun 19	81,325	16,332	22,191	11,256
31 Mar 19	81,593	14,679	22,437	11,229
30 Dec 18	81,581	15,297	22,540	10,775
30 Sep 18	81,382	1,542	22,454	11,194
01 Jul 18	80,684	1,372	22,300	11,271
01 Apr 18	78,693	1,245	21,758	10,928
31 Dec 17	76,450	1,300	21,520	10,594
01 Oct 17	74,361	15,827	20,600	9,591
02 Jul 17	72,531	16,335	20,012	9,184
02 Apr 17	72,174	16,505	20,020	9,152
01 Jan 17	71,890	16,540	19,793	9,143
02 Oct 16	71,595	15,941	20,527	9,319
03 Jul 16	70,877	15,027	20,836	9,295
03 Apr 16	70,182	15,546	21,044	9,160
03 Jan 16	70,074	15,409	21,203	9,046
27 Sep 15	70,517	14,715	21,134	8,817
28 Jun 15	71,882	16,106	21,521	8,686
29 Mar 15	73,590	15,916	21,618	8,562
28 Dec 14	74,331	16,323	21,954	8,494
28 Sep 14	74,232	17,321	22,049	8,270
29 Jun 14	73,340	15,554	21,895	8,289
30 Mar 14	71,722	15,061	21,790	8,230
29 Dec 13	71,312	13,831	21,830	8,183

Guadagni di qualità: JNJ ha un grande una tantum perdita di $7.9B che ha avuto un impatto sui suoi ultimi 12 mesi di risultati finanziari pari a 29th September, 2024.

Margine di profitto in crescita: Gli attuali margini di profitto netti di JNJ (16.8%) JNJ sono più alti rispetto allo scorso anno (14.8%).

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: Gli utili di JNJ sono diminuiti del 1.9% all'anno negli ultimi 5 anni.

Accelerare la crescita: La crescita degli utili di JNJ nell'ultimo anno ( 18.9% ) supera la media quinquennale ( -1.9% all'anno).

Guadagni vs Settore: La crescita degli utili JNJ nell'ultimo anno ( 18.9% ) non ha superato quella del settore Pharmaceuticals 54.6%.

Johnson & Johnson Performance dei guadagni passati

Il passato criteri di controllo 3/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Johnson & Johnson to Report Q4, 2024 Results on Jan 22, 2025

Recent updates

How To Build A $25,000 Dividend Portfolio, Johnson & Johnson As Your Core Holding

Johnson & Johnson Seeks U.S. FDA Approval for Subcutaneous Induction Regimen of Tremfya (Guselkumab) inulcerative Colitis, A First for an IL-23 Inhibitor

Johnson & Johnson: Policy Uncertainty Elevated, But Shares Remain Inexpensive

Upcoming dividend of US$1.24 per share

Johnson & Johnson Announces Results from Additional Analyses of the Phase 2 DAHLIA Study Highlighting Improvement in Key Measures of Disease Activity and IgG Reduction

Johnson & Johnson: Tracking Well Above The Industry

Johnson & Johnson Announces U.S. Food and Drug Administration Grants Nipocalimab Breakthrough Therapy Designation for the Treatment of Adults Living with Moderate-To-Severe Sjogren's Disease

Johnson & Johnson Submits Applications in the U.S. and EU Seek Approval of DARZALEX FASPRO® as Subcutaneous Monotherapy for High-Risk Smoldering Multiple Myeloma

Johnson & Johnson Announces Results from Phase 3 GRAVITI Study of Tremfya

Johnson & Johnson Highlights Innovative Neuropsychiatry Portfolio and Pipeline at Psych Congress

Johnson & Johnson Announces New Spectrem Study Findings Reveal Tremfya (Guselkumab) Effectively Clears Overlooked and Undertreated Plaque Psoriasis

Johnson & Johnson: Q3 Earnings Highlights Resilience And New Growth

Third quarter dividend of US$1.24 announced

Connecticut Jury Delivers $15 Million Asbestos Verdict Against Johnson & Johnson

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Johnson & Johnson Announces Positive Results from the Phase 2/3 Vibrance-MG Study of Nipocalimab

Johnson & Johnson Q3 Earnings Preview: Dividend Dependability And Steady Growth

Johnson & Johnson Announces Tremfya Data in Both Crohn's Disease and Ulcerative Colitis

Johnson & Johnson Announces the Results of A Landmark Real-World, Head-To-Head Study Showing That Erleada (Apalutamide)

Johnson & Johnson Files for U.S. FDA Approval of DARZALEX FASPRO-Based Quadruplet Regimen for Newly Diagnosed Multiple Myeloma Patients for Whom Transplant Is Not Planned

Johnson & Johnson Announces Data from Three Studies Highlighting Clinical Efficacy of Darzalex® (Daratumumab) and Darzalex Faspro in Maintenance Regimens

Johnson & Johnson: A Sell-Rated Dividend King

Johnson & Johnson Announces Interim Data from the Ongoing Phase 2 Sunrise-4 Study Showing Neoadjuvant Treatment with Investigational Tar-200 Plus Cetrelimab

Johnson & Johnson Announces Updated Results from the Phase 3 Mariposa-2 Study Which Showed Rybrevant (Amivantamab-Vmjw)

Johnson & Johnson Announces the Retirement of D. S. Davis as Director and Committee Changes

Why Investors Shouldn't Be Surprised By Johnson & Johnson's (NYSE:JNJ) P/E

Johnson & Johnson to Report Q4, 2024 Results on Jan 22, 2025

Johnson & Johnson Seeks First Approval of Nipocalimab to Treat Broadest Population Living with Antibody Positive Generalized Myasthenia Gravis

Johnson & Johnson Announces Executive Changes

Ripartizione dei ricavi e delle spese

Storia dei guadagni e delle entrate

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Rendimento del capitale proprio

Rendimento delle attività

Rendimento del capitale investito

Scoprire le aziende con forti performance passate